Review



pbabe puro ccnd1 ha  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Addgene inc pbabe puro ccnd1 ha
    CRISPR screening identified the cell-cycle pathway as the synthetic lethal pathway for mTORis in HNSCC. A, Scheme for CRISPR screening. Cal27-Cas9 cells were infected with the human kinome CRIPSR-knockout library, targeting 763 genes consisting of four sgRNAs for each gene, and subjected to vehicle treatment or INK128 treatment. At population doubling 20, genomic DNA was extracted from cells, and PCR and NGS were performed. B, Volcano plot of all dropout sgRNA hits. C, Extraction sequence of sensitizing sgRNA hits. The sensitizing hits were extracted with P value < 0.01 and analyzed with KEGG pathway analysis. D, Selected 109 hits plot. The hits included genes related to PI3K/mTOR and cell-cycle pathways. E, KEGG pathway analysis for sensitizing hits. KEGG pathway analysis was applied for significant 109 hits. The top 15 pathways are represented, and the color intensity of the bar represents the combined score. F, <t>CCND1</t> mRNA expression and OS in TCGA-HNSCC patients. Patients with high ( z -score > 0.5, n = 124) and low ( Z -score < 0.5, n = 73) expression of each mRNA were compared using the log-rank test. G, CCND1 RPPA expression and OS in TCGA-HNSCC patients. Patients with high ( z -score > 0.5, n = 120) and low ( z -score < 0.5, n = 120) expression of each mRNA were compared using the log-rank test. (Created with BioRender.com .)
    Pbabe Puro Ccnd1 Ha, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 9 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pbabe+puro+cyclind1+ha/pBABE+puro+cyclinD1+HA+(Plasmid+%239050)/pmc11284272-66-0-10
    Average 93 stars, based on 9 article reviews
    pbabe puro ccnd1 ha - by Bioz Stars, 2026-09
    93/100 stars

    Images

    1) Product Images from "A Kinome-Wide Synthetic Lethal CRISPR/Cas9 Screen Reveals That mTOR Inhibition Prevents Adaptive Resistance to CDK4/CDK6 Blockade in HNSCC"

    Article Title: A Kinome-Wide Synthetic Lethal CRISPR/Cas9 Screen Reveals That mTOR Inhibition Prevents Adaptive Resistance to CDK4/CDK6 Blockade in HNSCC

    Journal: Cancer Research Communications

    doi: 10.1158/2767-9764.CRC-24-0247

    CRISPR screening identified the cell-cycle pathway as the synthetic lethal pathway for mTORis in HNSCC. A, Scheme for CRISPR screening. Cal27-Cas9 cells were infected with the human kinome CRIPSR-knockout library, targeting 763 genes consisting of four sgRNAs for each gene, and subjected to vehicle treatment or INK128 treatment. At population doubling 20, genomic DNA was extracted from cells, and PCR and NGS were performed. B, Volcano plot of all dropout sgRNA hits. C, Extraction sequence of sensitizing sgRNA hits. The sensitizing hits were extracted with P value < 0.01 and analyzed with KEGG pathway analysis. D, Selected 109 hits plot. The hits included genes related to PI3K/mTOR and cell-cycle pathways. E, KEGG pathway analysis for sensitizing hits. KEGG pathway analysis was applied for significant 109 hits. The top 15 pathways are represented, and the color intensity of the bar represents the combined score. F, CCND1 mRNA expression and OS in TCGA-HNSCC patients. Patients with high ( z -score > 0.5, n = 124) and low ( Z -score < 0.5, n = 73) expression of each mRNA were compared using the log-rank test. G, CCND1 RPPA expression and OS in TCGA-HNSCC patients. Patients with high ( z -score > 0.5, n = 120) and low ( z -score < 0.5, n = 120) expression of each mRNA were compared using the log-rank test. (Created with BioRender.com .)
    Figure Legend Snippet: CRISPR screening identified the cell-cycle pathway as the synthetic lethal pathway for mTORis in HNSCC. A, Scheme for CRISPR screening. Cal27-Cas9 cells were infected with the human kinome CRIPSR-knockout library, targeting 763 genes consisting of four sgRNAs for each gene, and subjected to vehicle treatment or INK128 treatment. At population doubling 20, genomic DNA was extracted from cells, and PCR and NGS were performed. B, Volcano plot of all dropout sgRNA hits. C, Extraction sequence of sensitizing sgRNA hits. The sensitizing hits were extracted with P value < 0.01 and analyzed with KEGG pathway analysis. D, Selected 109 hits plot. The hits included genes related to PI3K/mTOR and cell-cycle pathways. E, KEGG pathway analysis for sensitizing hits. KEGG pathway analysis was applied for significant 109 hits. The top 15 pathways are represented, and the color intensity of the bar represents the combined score. F, CCND1 mRNA expression and OS in TCGA-HNSCC patients. Patients with high ( z -score > 0.5, n = 124) and low ( Z -score < 0.5, n = 73) expression of each mRNA were compared using the log-rank test. G, CCND1 RPPA expression and OS in TCGA-HNSCC patients. Patients with high ( z -score > 0.5, n = 120) and low ( z -score < 0.5, n = 120) expression of each mRNA were compared using the log-rank test. (Created with BioRender.com .)

    Techniques Used: CRISPR, Infection, Knock-Out, Extraction, Sequencing, Expressing

    Upregulation of CCNE1 by palbociclib confers resistance to palbociclib, which can be reverted by INK128. A, Relative mRNA levels of CCND1 and CCNE1 in Cal27 treated with INK128 and/or palbociclib for 24 hours. B, Signaling change with INK128 and/or palbociclib treatment. Cal27 cells were treated with 50 nmol/L of INK128, 1 µmol/L of palbociclib, or both for 48 hours after serum starvation overnight and were analyzed for indicated proteins by Western blotting. C, Cell viability of Cal27 cells treated with palbociclib. Comparison of wt, overexpressing CCND1, CCNE1, and both (mean ± SEM, n = 3). D, Cell viability of Cal27 cells treated with palbociclib. Comparison of wt, overexpressing CCNE1, and CCNE1+INK128 treatment (mean ± SEM, n = 3). E, eIF4G binding assay with INK128 and/or palbociclib treatment for CCNE1 . Proteins from each treated Cal27 were immunoprecipitated by eIF4G. RNA was extracted from the IP product, and expression of CCNE1 was determined by qPCR (mean ± SEM, n = 3). F, eIF4G binding assay with INK128 and/or palbociclib treatment for CCND1 . Proteins from each treated Cal27 were immunoprecipitated by eIF4G. RNA was extracted from the IP product, and expression of CCND1 was determined by qPCR (mean ± SEM, n = 3). G, Schema for CCND1 and CCNE1 mRNA translation. mTORC1 phosphorylates 4EBP1 and promotes mRNA translation. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns, nonsignificant. P value was determined using one-way ANOVA with the Tukey post hoc test in A . P value was determined using two-way ANOVA with the Tukey post hoc test in E and F . (Created with BioRender.com .)
    Figure Legend Snippet: Upregulation of CCNE1 by palbociclib confers resistance to palbociclib, which can be reverted by INK128. A, Relative mRNA levels of CCND1 and CCNE1 in Cal27 treated with INK128 and/or palbociclib for 24 hours. B, Signaling change with INK128 and/or palbociclib treatment. Cal27 cells were treated with 50 nmol/L of INK128, 1 µmol/L of palbociclib, or both for 48 hours after serum starvation overnight and were analyzed for indicated proteins by Western blotting. C, Cell viability of Cal27 cells treated with palbociclib. Comparison of wt, overexpressing CCND1, CCNE1, and both (mean ± SEM, n = 3). D, Cell viability of Cal27 cells treated with palbociclib. Comparison of wt, overexpressing CCNE1, and CCNE1+INK128 treatment (mean ± SEM, n = 3). E, eIF4G binding assay with INK128 and/or palbociclib treatment for CCNE1 . Proteins from each treated Cal27 were immunoprecipitated by eIF4G. RNA was extracted from the IP product, and expression of CCNE1 was determined by qPCR (mean ± SEM, n = 3). F, eIF4G binding assay with INK128 and/or palbociclib treatment for CCND1 . Proteins from each treated Cal27 were immunoprecipitated by eIF4G. RNA was extracted from the IP product, and expression of CCND1 was determined by qPCR (mean ± SEM, n = 3). G, Schema for CCND1 and CCNE1 mRNA translation. mTORC1 phosphorylates 4EBP1 and promotes mRNA translation. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns, nonsignificant. P value was determined using one-way ANOVA with the Tukey post hoc test in A . P value was determined using two-way ANOVA with the Tukey post hoc test in E and F . (Created with BioRender.com .)

    Techniques Used: Western Blot, Comparison, Binding Assay, Immunoprecipitation, Expressing

    Combination therapy with INK128 and palbociclib is effective against HNSCC xenografts. A, Tumor growth curve for HN12 xenografts treated with INK128, palbociclib, and combination (mean ± SEM, n = 10). B, Hematoxylin and eosin staining of HN12 xenograft tumors. C, BrdU staining for HN12 xenograft tumors. The percentage of BrdU-positive cells was compared by treatment group (mean ± SEM, n = 3). D, Representative IHC staining images of HN12 xenografts (strongly magnified). Tumors were stained with hematoxylin–eosin (HE), pS6, p4EBP1, CCND1, and CCNE1. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05, ns, nonsignificant. P value was determined using one-way ANOVA with the Tukey post hoc test in A and C . (Created with BioRender.com .)
    Figure Legend Snippet: Combination therapy with INK128 and palbociclib is effective against HNSCC xenografts. A, Tumor growth curve for HN12 xenografts treated with INK128, palbociclib, and combination (mean ± SEM, n = 10). B, Hematoxylin and eosin staining of HN12 xenograft tumors. C, BrdU staining for HN12 xenograft tumors. The percentage of BrdU-positive cells was compared by treatment group (mean ± SEM, n = 3). D, Representative IHC staining images of HN12 xenografts (strongly magnified). Tumors were stained with hematoxylin–eosin (HE), pS6, p4EBP1, CCND1, and CCNE1. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05, ns, nonsignificant. P value was determined using one-way ANOVA with the Tukey post hoc test in A and C . (Created with BioRender.com .)

    Techniques Used: Staining, BrdU Staining, Immunohistochemistry

    Related Articles

    Plasmid Preparation:

    Article Title: Assessment of different strategies for scalable production and proliferation of human myoblasts.
    Article Snippet: 24‐hour post‐ transfection, growth medium was replaced with DMEM (Gibco) with 20% FBS (GE), 1% l‐glutamine (Gibco) and 1% penicillin‐ streptomycin (Gibco). .. The following plasmids were used to make the viruses: pBABE‐MDER (gift from Stephen Tapscott; Addgene plasmid #13494), pBABE‐neo‐hTERT (gift from Bob Weinberg; Addgene plasmid #1774), pBABE‐hygro CDK4 R24C (gift from Bob Weinberg; Addgene plasmid #11254) and pBABE puro cyclinD1 HA (gift from William Hahn; Addgene plasmid #9050). .. 2.2 | Virus transduction and selection HSKM myoblasts were seeded in six‐well plates (Falcon) in growth medium comprising of DMEM‐F12 (Gibco) with 20% heat‐inactivated FBS (GE), 1% l‐glutamine (Gibco) and 1% penicillin‐streptomycin (Gibco).

    Article Title: Assessment of different strategies for scalable production and proliferation of human myoblasts
    Article Snippet: 24‐hour post‐transfection, growth medium was replaced with DMEM (Gibco) with 20% FBS (GE), 1% l ‐glutamine (Gibco) and 1% penicillin‐streptomycin (Gibco). .. The following plasmids were used to make the viruses: pBABE‐MDER (gift from Stephen Tapscott; Addgene plasmid #13494), pBABE‐neo‐hTERT (gift from Bob Weinberg; Addgene plasmid #1774), pBABE‐hygro CDK4 R24C (gift from Bob Weinberg; Addgene plasmid #11254) and pBABE puro cyclinD1 HA (gift from William Hahn; Addgene plasmid #9050). .. HSKM myoblasts were seeded in six‐well plates (Falcon) in growth medium comprising of DMEM‐F12 (Gibco) with 20% heat‐inactivated FBS (GE), 1% l ‐glutamine (Gibco) and 1% penicillin‐streptomycin (Gibco).

    Article Title: Analysis of post-transcriptional regulation during cancer progression using a donor-derived isogenic model of tumorigenesis
    Article Snippet: .. Alternatively, all pBabe empty vector backbones with all appropriate selection markers are publicly available from Addgene, and one could easily clone vectors of interest p0467/pCL-10A1 viral packaging plasmid (gift of Dr. Chris Counter; can be obtained from Novus Biologicals, catalog #NBP2–29542) pBabe-hygro-hTERT (addgene plasmid #1773, gift of Dr. Bob Weinberg [ 30 ]) pBabe-neo-p53 DD (gift of Dr. Chris Counter [ 8 , 31 ]) pBabe-puro-cyclinD1-HA (addgene plasmid #9050, gift of Dr. William Hahn) pBabe-bleo-CDK4 R24C -HA (gift of Dr. Chris Counter [ 8 , 31 ]) pBabe-blast-c-myc (gift of Dr. Chris Counter [ 8 , 32 ]) pBabe-YFP-FLAG-HRAS G12V (gift of Dr. Chris Counter [ 27 ]) pBabe-GFP control (addgene plasmid #10668, gift of Dr. William Hahn) 2.1.3. ..

    Article Title: Analysis of post-transcriptional regulation during cancer progression using a donor-derived isogenic model of tumorigenesis
    Article Snippet: .. Alternatively, all pBabe empty vector backbones with all appropriate selection markers are publicly available from Addgene, and one could easily clone vectors of interest list-behavior=unordered prefix-word= mark-type=disc max-label-size=0 p0467/pCL-10A1 viral packaging plasmid (gift of Dr. Chris Counter; can be obtained from Novus Biologicals, catalog #NBP2–29542) pBabe-hygro-hTERT (addgene plasmid #1773, gift of Dr. Bob Weinberg [ 30 ]) pBabe-neo-p53 DD (gift of Dr. Chris Counter [ 8 , 31 ]) pBabe-puro-cyclinD1-HA (addgene plasmid #9050, gift of Dr. William Hahn) pBabe-bleo-CDK4 R24C -HA (gift of Dr. Chris Counter [ 8 , 31 ]) pBabe-blast-c-myc (gift of Dr. Chris Counter [ 8 , 32 ]) pBabe-YFP-FLAG-HRAS G12V (gift of Dr. Chris Counter [ 27 ]) pBabe-GFP control (addgene plasmid #10668, gift of Dr. William Hahn) 2.1.3. ..

    Article Title: Analysis of post-transcriptional regulation during cancer progression using a donor-derived isogenic model of tumorigenesis
    Article Snippet: .. Alternatively, all pBabe empty vector backbones with all appropriate selection markers are publicly available from Addgene, and one could easily clone vectors of interest p0467/pCL-10A1 viral packaging plasmid (gift of Dr. Chris Counter; can be obtained from Novus Biologicals, catalog #NBP2–29542) pBabe-hygro-hTERT (addgene plasmid #1773, gift of Dr. Bob Weinberg [ 30 ]) pBabe-neo-p53 DD (gift of Dr. Chris Counter [ 8 , 31 ]) pBabe-puro-cyclinD1-HA (addgene plasmid #9050, gift of Dr. William Hahn) pBabe-bleo-CDK4 R24C -HA (gift of Dr. Chris Counter [ 8 , 31 ]) pBabe-blast-c-myc (gift of Dr. Chris Counter [ 8 , 32 ]) pBabe-YFP-FLAG-HRAS G12V (gift of Dr. Chris Counter [ 27 ]) pBabe-GFP control (addgene plasmid #10668, gift of Dr. William Hahn) ..

    Construct:

    Article Title: The LIM-Only Protein FHL2 Mediates Ras-Induced Transformation through Cyclin D1 and p53 Pathways
    Article Snippet: .. The pBabe-hygro p53DD construct from Dr. Bob Weinberg's lab and the pBabe-puro-cyclinD1-HA from Dr. William Hahn's lab were obtained from Addgene (Addgene plasmids 9058 and 9050 respectively). ..

    Selection:

    Article Title: Analysis of post-transcriptional regulation during cancer progression using a donor-derived isogenic model of tumorigenesis
    Article Snippet: .. Alternatively, all pBabe empty vector backbones with all appropriate selection markers are publicly available from Addgene, and one could easily clone vectors of interest p0467/pCL-10A1 viral packaging plasmid (gift of Dr. Chris Counter; can be obtained from Novus Biologicals, catalog #NBP2–29542) pBabe-hygro-hTERT (addgene plasmid #1773, gift of Dr. Bob Weinberg [ 30 ]) pBabe-neo-p53 DD (gift of Dr. Chris Counter [ 8 , 31 ]) pBabe-puro-cyclinD1-HA (addgene plasmid #9050, gift of Dr. William Hahn) pBabe-bleo-CDK4 R24C -HA (gift of Dr. Chris Counter [ 8 , 31 ]) pBabe-blast-c-myc (gift of Dr. Chris Counter [ 8 , 32 ]) pBabe-YFP-FLAG-HRAS G12V (gift of Dr. Chris Counter [ 27 ]) pBabe-GFP control (addgene plasmid #10668, gift of Dr. William Hahn) 2.1.3. ..

    Article Title: Analysis of post-transcriptional regulation during cancer progression using a donor-derived isogenic model of tumorigenesis
    Article Snippet: .. Alternatively, all pBabe empty vector backbones with all appropriate selection markers are publicly available from Addgene, and one could easily clone vectors of interest list-behavior=unordered prefix-word= mark-type=disc max-label-size=0 p0467/pCL-10A1 viral packaging plasmid (gift of Dr. Chris Counter; can be obtained from Novus Biologicals, catalog #NBP2–29542) pBabe-hygro-hTERT (addgene plasmid #1773, gift of Dr. Bob Weinberg [ 30 ]) pBabe-neo-p53 DD (gift of Dr. Chris Counter [ 8 , 31 ]) pBabe-puro-cyclinD1-HA (addgene plasmid #9050, gift of Dr. William Hahn) pBabe-bleo-CDK4 R24C -HA (gift of Dr. Chris Counter [ 8 , 31 ]) pBabe-blast-c-myc (gift of Dr. Chris Counter [ 8 , 32 ]) pBabe-YFP-FLAG-HRAS G12V (gift of Dr. Chris Counter [ 27 ]) pBabe-GFP control (addgene plasmid #10668, gift of Dr. William Hahn) 2.1.3. ..

    Article Title: Analysis of post-transcriptional regulation during cancer progression using a donor-derived isogenic model of tumorigenesis
    Article Snippet: .. Alternatively, all pBabe empty vector backbones with all appropriate selection markers are publicly available from Addgene, and one could easily clone vectors of interest p0467/pCL-10A1 viral packaging plasmid (gift of Dr. Chris Counter; can be obtained from Novus Biologicals, catalog #NBP2–29542) pBabe-hygro-hTERT (addgene plasmid #1773, gift of Dr. Bob Weinberg [ 30 ]) pBabe-neo-p53 DD (gift of Dr. Chris Counter [ 8 , 31 ]) pBabe-puro-cyclinD1-HA (addgene plasmid #9050, gift of Dr. William Hahn) pBabe-bleo-CDK4 R24C -HA (gift of Dr. Chris Counter [ 8 , 31 ]) pBabe-blast-c-myc (gift of Dr. Chris Counter [ 8 , 32 ]) pBabe-YFP-FLAG-HRAS G12V (gift of Dr. Chris Counter [ 27 ]) pBabe-GFP control (addgene plasmid #10668, gift of Dr. William Hahn) ..

    Control:

    Article Title: Analysis of post-transcriptional regulation during cancer progression using a donor-derived isogenic model of tumorigenesis
    Article Snippet: .. Alternatively, all pBabe empty vector backbones with all appropriate selection markers are publicly available from Addgene, and one could easily clone vectors of interest p0467/pCL-10A1 viral packaging plasmid (gift of Dr. Chris Counter; can be obtained from Novus Biologicals, catalog #NBP2–29542) pBabe-hygro-hTERT (addgene plasmid #1773, gift of Dr. Bob Weinberg [ 30 ]) pBabe-neo-p53 DD (gift of Dr. Chris Counter [ 8 , 31 ]) pBabe-puro-cyclinD1-HA (addgene plasmid #9050, gift of Dr. William Hahn) pBabe-bleo-CDK4 R24C -HA (gift of Dr. Chris Counter [ 8 , 31 ]) pBabe-blast-c-myc (gift of Dr. Chris Counter [ 8 , 32 ]) pBabe-YFP-FLAG-HRAS G12V (gift of Dr. Chris Counter [ 27 ]) pBabe-GFP control (addgene plasmid #10668, gift of Dr. William Hahn) 2.1.3. ..

    Article Title: Analysis of post-transcriptional regulation during cancer progression using a donor-derived isogenic model of tumorigenesis
    Article Snippet: .. Alternatively, all pBabe empty vector backbones with all appropriate selection markers are publicly available from Addgene, and one could easily clone vectors of interest list-behavior=unordered prefix-word= mark-type=disc max-label-size=0 p0467/pCL-10A1 viral packaging plasmid (gift of Dr. Chris Counter; can be obtained from Novus Biologicals, catalog #NBP2–29542) pBabe-hygro-hTERT (addgene plasmid #1773, gift of Dr. Bob Weinberg [ 30 ]) pBabe-neo-p53 DD (gift of Dr. Chris Counter [ 8 , 31 ]) pBabe-puro-cyclinD1-HA (addgene plasmid #9050, gift of Dr. William Hahn) pBabe-bleo-CDK4 R24C -HA (gift of Dr. Chris Counter [ 8 , 31 ]) pBabe-blast-c-myc (gift of Dr. Chris Counter [ 8 , 32 ]) pBabe-YFP-FLAG-HRAS G12V (gift of Dr. Chris Counter [ 27 ]) pBabe-GFP control (addgene plasmid #10668, gift of Dr. William Hahn) 2.1.3. ..

    Article Title: Analysis of post-transcriptional regulation during cancer progression using a donor-derived isogenic model of tumorigenesis
    Article Snippet: .. Alternatively, all pBabe empty vector backbones with all appropriate selection markers are publicly available from Addgene, and one could easily clone vectors of interest p0467/pCL-10A1 viral packaging plasmid (gift of Dr. Chris Counter; can be obtained from Novus Biologicals, catalog #NBP2–29542) pBabe-hygro-hTERT (addgene plasmid #1773, gift of Dr. Bob Weinberg [ 30 ]) pBabe-neo-p53 DD (gift of Dr. Chris Counter [ 8 , 31 ]) pBabe-puro-cyclinD1-HA (addgene plasmid #9050, gift of Dr. William Hahn) pBabe-bleo-CDK4 R24C -HA (gift of Dr. Chris Counter [ 8 , 31 ]) pBabe-blast-c-myc (gift of Dr. Chris Counter [ 8 , 32 ]) pBabe-YFP-FLAG-HRAS G12V (gift of Dr. Chris Counter [ 27 ]) pBabe-GFP control (addgene plasmid #10668, gift of Dr. William Hahn) ..



    Similar Products

    93
    Addgene inc pbabe puro ccnd1 ha
    CRISPR screening identified the cell-cycle pathway as the synthetic lethal pathway for mTORis in HNSCC. A, Scheme for CRISPR screening. Cal27-Cas9 cells were infected with the human kinome CRIPSR-knockout library, targeting 763 genes consisting of four sgRNAs for each gene, and subjected to vehicle treatment or INK128 treatment. At population doubling 20, genomic DNA was extracted from cells, and PCR and NGS were performed. B, Volcano plot of all dropout sgRNA hits. C, Extraction sequence of sensitizing sgRNA hits. The sensitizing hits were extracted with P value < 0.01 and analyzed with KEGG pathway analysis. D, Selected 109 hits plot. The hits included genes related to PI3K/mTOR and cell-cycle pathways. E, KEGG pathway analysis for sensitizing hits. KEGG pathway analysis was applied for significant 109 hits. The top 15 pathways are represented, and the color intensity of the bar represents the combined score. F, <t>CCND1</t> mRNA expression and OS in TCGA-HNSCC patients. Patients with high ( z -score > 0.5, n = 124) and low ( Z -score < 0.5, n = 73) expression of each mRNA were compared using the log-rank test. G, CCND1 RPPA expression and OS in TCGA-HNSCC patients. Patients with high ( z -score > 0.5, n = 120) and low ( z -score < 0.5, n = 120) expression of each mRNA were compared using the log-rank test. (Created with BioRender.com .)
    Pbabe Puro Ccnd1 Ha, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pbabe+puro+cyclind1+ha/pBABE+puro+cyclinD1+HA+(Plasmid+%239050)/pmc11284272-66-0-10
    Average 93 stars, based on 1 article reviews
    pbabe puro ccnd1 ha - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    93
    Addgene inc ha cyclin d1
    CRISPR screening identified the cell-cycle pathway as the synthetic lethal pathway for mTORis in HNSCC. A, Scheme for CRISPR screening. Cal27-Cas9 cells were infected with the human kinome CRIPSR-knockout library, targeting 763 genes consisting of four sgRNAs for each gene, and subjected to vehicle treatment or INK128 treatment. At population doubling 20, genomic DNA was extracted from cells, and PCR and NGS were performed. B, Volcano plot of all dropout sgRNA hits. C, Extraction sequence of sensitizing sgRNA hits. The sensitizing hits were extracted with P value < 0.01 and analyzed with KEGG pathway analysis. D, Selected 109 hits plot. The hits included genes related to PI3K/mTOR and cell-cycle pathways. E, KEGG pathway analysis for sensitizing hits. KEGG pathway analysis was applied for significant 109 hits. The top 15 pathways are represented, and the color intensity of the bar represents the combined score. F, <t>CCND1</t> mRNA expression and OS in TCGA-HNSCC patients. Patients with high ( z -score > 0.5, n = 124) and low ( Z -score < 0.5, n = 73) expression of each mRNA were compared using the log-rank test. G, CCND1 RPPA expression and OS in TCGA-HNSCC patients. Patients with high ( z -score > 0.5, n = 120) and low ( z -score < 0.5, n = 120) expression of each mRNA were compared using the log-rank test. (Created with BioRender.com .)
    Ha Cyclin D1, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pbabe+puro+cyclind1+ha/pBABE+puro+cyclinD1+HA+(Plasmid+%239050)/pm39027231-88-3-13
    Average 93 stars, based on 1 article reviews
    ha cyclin d1 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    93
    Addgene inc pbabe puro cyclind1 ha
    CRISPR screening identified the cell-cycle pathway as the synthetic lethal pathway for mTORis in HNSCC. A, Scheme for CRISPR screening. Cal27-Cas9 cells were infected with the human kinome CRIPSR-knockout library, targeting 763 genes consisting of four sgRNAs for each gene, and subjected to vehicle treatment or INK128 treatment. At population doubling 20, genomic DNA was extracted from cells, and PCR and NGS were performed. B, Volcano plot of all dropout sgRNA hits. C, Extraction sequence of sensitizing sgRNA hits. The sensitizing hits were extracted with P value < 0.01 and analyzed with KEGG pathway analysis. D, Selected 109 hits plot. The hits included genes related to PI3K/mTOR and cell-cycle pathways. E, KEGG pathway analysis for sensitizing hits. KEGG pathway analysis was applied for significant 109 hits. The top 15 pathways are represented, and the color intensity of the bar represents the combined score. F, <t>CCND1</t> mRNA expression and OS in TCGA-HNSCC patients. Patients with high ( z -score > 0.5, n = 124) and low ( Z -score < 0.5, n = 73) expression of each mRNA were compared using the log-rank test. G, CCND1 RPPA expression and OS in TCGA-HNSCC patients. Patients with high ( z -score > 0.5, n = 120) and low ( z -score < 0.5, n = 120) expression of each mRNA were compared using the log-rank test. (Created with BioRender.com .)
    Pbabe Puro Cyclind1 Ha, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pbabe+puro+cyclind1+ha/pBABE+puro+cyclinD1+HA+(Plasmid+%239050)/pm30891802-33-36-44
    Average 93 stars, based on 1 article reviews
    pbabe puro cyclind1 ha - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    93
    Addgene inc pbabe puro cyclind1
    CRISPR screening identified the cell-cycle pathway as the synthetic lethal pathway for mTORis in HNSCC. A, Scheme for CRISPR screening. Cal27-Cas9 cells were infected with the human kinome CRIPSR-knockout library, targeting 763 genes consisting of four sgRNAs for each gene, and subjected to vehicle treatment or INK128 treatment. At population doubling 20, genomic DNA was extracted from cells, and PCR and NGS were performed. B, Volcano plot of all dropout sgRNA hits. C, Extraction sequence of sensitizing sgRNA hits. The sensitizing hits were extracted with P value < 0.01 and analyzed with KEGG pathway analysis. D, Selected 109 hits plot. The hits included genes related to PI3K/mTOR and cell-cycle pathways. E, KEGG pathway analysis for sensitizing hits. KEGG pathway analysis was applied for significant 109 hits. The top 15 pathways are represented, and the color intensity of the bar represents the combined score. F, <t>CCND1</t> mRNA expression and OS in TCGA-HNSCC patients. Patients with high ( z -score > 0.5, n = 124) and low ( Z -score < 0.5, n = 73) expression of each mRNA were compared using the log-rank test. G, CCND1 RPPA expression and OS in TCGA-HNSCC patients. Patients with high ( z -score > 0.5, n = 120) and low ( z -score < 0.5, n = 120) expression of each mRNA were compared using the log-rank test. (Created with BioRender.com .)
    Pbabe Puro Cyclind1, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pbabe+puro+cyclind1+ha/pBABE+puro+cyclinD1+HA+(Plasmid+%239050)/pmc06118591-548-28-42
    Average 93 stars, based on 1 article reviews
    pbabe puro cyclind1 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    Image Search Results


    CRISPR screening identified the cell-cycle pathway as the synthetic lethal pathway for mTORis in HNSCC. A, Scheme for CRISPR screening. Cal27-Cas9 cells were infected with the human kinome CRIPSR-knockout library, targeting 763 genes consisting of four sgRNAs for each gene, and subjected to vehicle treatment or INK128 treatment. At population doubling 20, genomic DNA was extracted from cells, and PCR and NGS were performed. B, Volcano plot of all dropout sgRNA hits. C, Extraction sequence of sensitizing sgRNA hits. The sensitizing hits were extracted with P value < 0.01 and analyzed with KEGG pathway analysis. D, Selected 109 hits plot. The hits included genes related to PI3K/mTOR and cell-cycle pathways. E, KEGG pathway analysis for sensitizing hits. KEGG pathway analysis was applied for significant 109 hits. The top 15 pathways are represented, and the color intensity of the bar represents the combined score. F, CCND1 mRNA expression and OS in TCGA-HNSCC patients. Patients with high ( z -score > 0.5, n = 124) and low ( Z -score < 0.5, n = 73) expression of each mRNA were compared using the log-rank test. G, CCND1 RPPA expression and OS in TCGA-HNSCC patients. Patients with high ( z -score > 0.5, n = 120) and low ( z -score < 0.5, n = 120) expression of each mRNA were compared using the log-rank test. (Created with BioRender.com .)

    Journal: Cancer Research Communications

    Article Title: A Kinome-Wide Synthetic Lethal CRISPR/Cas9 Screen Reveals That mTOR Inhibition Prevents Adaptive Resistance to CDK4/CDK6 Blockade in HNSCC

    doi: 10.1158/2767-9764.CRC-24-0247

    Figure Lengend Snippet: CRISPR screening identified the cell-cycle pathway as the synthetic lethal pathway for mTORis in HNSCC. A, Scheme for CRISPR screening. Cal27-Cas9 cells were infected with the human kinome CRIPSR-knockout library, targeting 763 genes consisting of four sgRNAs for each gene, and subjected to vehicle treatment or INK128 treatment. At population doubling 20, genomic DNA was extracted from cells, and PCR and NGS were performed. B, Volcano plot of all dropout sgRNA hits. C, Extraction sequence of sensitizing sgRNA hits. The sensitizing hits were extracted with P value < 0.01 and analyzed with KEGG pathway analysis. D, Selected 109 hits plot. The hits included genes related to PI3K/mTOR and cell-cycle pathways. E, KEGG pathway analysis for sensitizing hits. KEGG pathway analysis was applied for significant 109 hits. The top 15 pathways are represented, and the color intensity of the bar represents the combined score. F, CCND1 mRNA expression and OS in TCGA-HNSCC patients. Patients with high ( z -score > 0.5, n = 124) and low ( Z -score < 0.5, n = 73) expression of each mRNA were compared using the log-rank test. G, CCND1 RPPA expression and OS in TCGA-HNSCC patients. Patients with high ( z -score > 0.5, n = 120) and low ( z -score < 0.5, n = 120) expression of each mRNA were compared using the log-rank test. (Created with BioRender.com .)

    Article Snippet: pBABE puro CCND1 HA was a gift from William Hahn (Addgene plasmid # 9050; RRID: Addgene_9050). pInducer20 CCNE1 was a gift from Jean Cook (Addgene plasmid # 109348; RRID: Addgene_109348).

    Techniques: CRISPR, Infection, Knock-Out, Extraction, Sequencing, Expressing

    Upregulation of CCNE1 by palbociclib confers resistance to palbociclib, which can be reverted by INK128. A, Relative mRNA levels of CCND1 and CCNE1 in Cal27 treated with INK128 and/or palbociclib for 24 hours. B, Signaling change with INK128 and/or palbociclib treatment. Cal27 cells were treated with 50 nmol/L of INK128, 1 µmol/L of palbociclib, or both for 48 hours after serum starvation overnight and were analyzed for indicated proteins by Western blotting. C, Cell viability of Cal27 cells treated with palbociclib. Comparison of wt, overexpressing CCND1, CCNE1, and both (mean ± SEM, n = 3). D, Cell viability of Cal27 cells treated with palbociclib. Comparison of wt, overexpressing CCNE1, and CCNE1+INK128 treatment (mean ± SEM, n = 3). E, eIF4G binding assay with INK128 and/or palbociclib treatment for CCNE1 . Proteins from each treated Cal27 were immunoprecipitated by eIF4G. RNA was extracted from the IP product, and expression of CCNE1 was determined by qPCR (mean ± SEM, n = 3). F, eIF4G binding assay with INK128 and/or palbociclib treatment for CCND1 . Proteins from each treated Cal27 were immunoprecipitated by eIF4G. RNA was extracted from the IP product, and expression of CCND1 was determined by qPCR (mean ± SEM, n = 3). G, Schema for CCND1 and CCNE1 mRNA translation. mTORC1 phosphorylates 4EBP1 and promotes mRNA translation. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns, nonsignificant. P value was determined using one-way ANOVA with the Tukey post hoc test in A . P value was determined using two-way ANOVA with the Tukey post hoc test in E and F . (Created with BioRender.com .)

    Journal: Cancer Research Communications

    Article Title: A Kinome-Wide Synthetic Lethal CRISPR/Cas9 Screen Reveals That mTOR Inhibition Prevents Adaptive Resistance to CDK4/CDK6 Blockade in HNSCC

    doi: 10.1158/2767-9764.CRC-24-0247

    Figure Lengend Snippet: Upregulation of CCNE1 by palbociclib confers resistance to palbociclib, which can be reverted by INK128. A, Relative mRNA levels of CCND1 and CCNE1 in Cal27 treated with INK128 and/or palbociclib for 24 hours. B, Signaling change with INK128 and/or palbociclib treatment. Cal27 cells were treated with 50 nmol/L of INK128, 1 µmol/L of palbociclib, or both for 48 hours after serum starvation overnight and were analyzed for indicated proteins by Western blotting. C, Cell viability of Cal27 cells treated with palbociclib. Comparison of wt, overexpressing CCND1, CCNE1, and both (mean ± SEM, n = 3). D, Cell viability of Cal27 cells treated with palbociclib. Comparison of wt, overexpressing CCNE1, and CCNE1+INK128 treatment (mean ± SEM, n = 3). E, eIF4G binding assay with INK128 and/or palbociclib treatment for CCNE1 . Proteins from each treated Cal27 were immunoprecipitated by eIF4G. RNA was extracted from the IP product, and expression of CCNE1 was determined by qPCR (mean ± SEM, n = 3). F, eIF4G binding assay with INK128 and/or palbociclib treatment for CCND1 . Proteins from each treated Cal27 were immunoprecipitated by eIF4G. RNA was extracted from the IP product, and expression of CCND1 was determined by qPCR (mean ± SEM, n = 3). G, Schema for CCND1 and CCNE1 mRNA translation. mTORC1 phosphorylates 4EBP1 and promotes mRNA translation. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns, nonsignificant. P value was determined using one-way ANOVA with the Tukey post hoc test in A . P value was determined using two-way ANOVA with the Tukey post hoc test in E and F . (Created with BioRender.com .)

    Article Snippet: pBABE puro CCND1 HA was a gift from William Hahn (Addgene plasmid # 9050; RRID: Addgene_9050). pInducer20 CCNE1 was a gift from Jean Cook (Addgene plasmid # 109348; RRID: Addgene_109348).

    Techniques: Western Blot, Comparison, Binding Assay, Immunoprecipitation, Expressing

    Combination therapy with INK128 and palbociclib is effective against HNSCC xenografts. A, Tumor growth curve for HN12 xenografts treated with INK128, palbociclib, and combination (mean ± SEM, n = 10). B, Hematoxylin and eosin staining of HN12 xenograft tumors. C, BrdU staining for HN12 xenograft tumors. The percentage of BrdU-positive cells was compared by treatment group (mean ± SEM, n = 3). D, Representative IHC staining images of HN12 xenografts (strongly magnified). Tumors were stained with hematoxylin–eosin (HE), pS6, p4EBP1, CCND1, and CCNE1. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05, ns, nonsignificant. P value was determined using one-way ANOVA with the Tukey post hoc test in A and C . (Created with BioRender.com .)

    Journal: Cancer Research Communications

    Article Title: A Kinome-Wide Synthetic Lethal CRISPR/Cas9 Screen Reveals That mTOR Inhibition Prevents Adaptive Resistance to CDK4/CDK6 Blockade in HNSCC

    doi: 10.1158/2767-9764.CRC-24-0247

    Figure Lengend Snippet: Combination therapy with INK128 and palbociclib is effective against HNSCC xenografts. A, Tumor growth curve for HN12 xenografts treated with INK128, palbociclib, and combination (mean ± SEM, n = 10). B, Hematoxylin and eosin staining of HN12 xenograft tumors. C, BrdU staining for HN12 xenograft tumors. The percentage of BrdU-positive cells was compared by treatment group (mean ± SEM, n = 3). D, Representative IHC staining images of HN12 xenografts (strongly magnified). Tumors were stained with hematoxylin–eosin (HE), pS6, p4EBP1, CCND1, and CCNE1. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05, ns, nonsignificant. P value was determined using one-way ANOVA with the Tukey post hoc test in A and C . (Created with BioRender.com .)

    Article Snippet: pBABE puro CCND1 HA was a gift from William Hahn (Addgene plasmid # 9050; RRID: Addgene_9050). pInducer20 CCNE1 was a gift from Jean Cook (Addgene plasmid # 109348; RRID: Addgene_109348).

    Techniques: Staining, BrdU Staining, Immunohistochemistry